Crossject S.A. is a pharmaceutical company specializing in the development of needle-free, pre-filled delivery systems known as Zeneo injectors. Its primary function is to provide a pain-free, user-friendly alternative to traditional hypodermic injection methods, aiming to enhance patient compliance and accessibility. The company's technology serves vital sectors in healthcare, impacting areas such as emergency medicine, chronic disease management, and biodefense. By eliminating the need for needles, Crossject's products address concerns related to needle-phobia, safety, and disposal challenges. With its pioneering delivery innovation, Crossject S.A. holds a significant role in the pharmaceutical market by potentially revolutionizing the administration of life-saving medications, enhancing care outcomes, and expanding access to treatments in various settings.